

FOR OFFICIAL USE ONLY

ACCESS DB # 155979
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

mej

Requester's Full Name: Jeffrey E. Russell Examiner #: 62785 Date: June 9, 2005
Art Unit: 1654 Phone Number: 2-0969 Serial Number: 10/671,340
Location (Bldg/Room#): REN 3 D19 (Mailbox #): 3C18 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Modified GLP-1 Reptides With Increased Biological Potency
Inventors (please provide full names): D. Gravel, K. Per, T. Atribat, A. Habi



Earliest Priority Date: 9-25-2003

Search Topic:


Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search the following partial structures



where ~~R2~~ R2 and R3 are OCH3, OCH2CH3, OH, NH2, -NH-C6H5, or halogen.



Please narrow any hits by requiring A to be
or by using the keywords GLP-1 / glucagon-like peptide-1.

Thank you
fzk

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

____ Structure (#)

____ Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

____ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis

____ Westlaw _____ WWW/Internet


____ In-house sequence systems

____ Commercial _____ Oligomer _____ Score/Length
____ Interference _____ SPDI _____ Encode/Transl
____ Other (specify)

Russel
10/671340

Page 1

=> d 13 que stat;fil medl,biosis,embase,caplus;s 13
L1 STR




G2 @32

26

Page 1-A

Me
4

Page 1-B



Page 2-A

REP G1=(0-1) CH2
VAR G2=20/22/OH/NH2/31
VPA 32-4/5 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L3 46 SEA FILE=REGISTRY SSS FUL L1

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

100.0% PROCESSED 83477 ITERATIONS
SEARCH TIME: 00.00.02

46 ANSWERS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	163.91	164.12

FILE 'MEDLINE' ENTERED AT 11:17:29 ON 22 JUN 2005

FILE 'BIOSIS' ENTERED AT 11:17:29 ON 22 JUN 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:17:29 ON 22 JUN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 11:17:29 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

L4	0 FILE MEDLINE
L5	0 FILE BIOSIS
L6	0 FILE EMBASE
L7	33 FILE CAPLUS

TOTAL FOR ALL FILES
L8 33 L3

=> fil caplus;s l8 and (glp1 or (glucagon like peptide(w)1))

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.76	169.88

FILE 'CAPLUS' ENTERED AT 11:18:52 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2005 VOL 142 ISS 26
FILE LAST UPDATED: 21 Jun 2005 (20050621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

701 GLP1
23851 GLUCAGON
103 GLUCAGONS
23864 GLUCAGON
 (GLUCAGON OR GLUCAGONS)
672456 LIKE
 252 LIKES
672671 LIKE
 (LIKE OR LIKES)
331383 PEPTIDE
242343 PEPTIDES
424312 PEPTIDE
 (PEPTIDE OR PEPTIDES)
2541 GLUCAGON LIKE PEPTIDE
 (GLUCAGON(W)LIKE(W)PEPTIDE)
8306103 1
 1796 GLUCAGON LIKE PEPTIDE(W)1
L9 1 L7 AND (GLP1 OR (GLUCAGON LIKE PEPTIDE(W)1))

=> d ibib abs hitstr

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:287858 CAPLUS
 DOCUMENT NUMBER: 140:298100
 TITLE: Modified GLP-1 peptides with increased biol. potency in the treatment of glucose metabolism disorders, insulin resistance, and related conditions
 INVENTOR(S): Gravel, Denis; Peri, Krishna; Abribat, Thierry; Habi, Abdelkrim
 PATENT ASSIGNEE(S): Theratechnologies Inc., Can.
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029081	A2	20040408	WO 2003-CA1470	20030925
WO 2004029081	A3	20040722		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004127412 A1 20040701 US 2003-671340 20030925
 PRIORITY APPLN. INFO.: US 2002-41317P P 20020925


OTHER SOURCE(S): MARPAT 140:298100
 AB The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:
 X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Y (SEQ ID NO.1), wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH₂ and Gly-OH. Moreover, the present invention relates to pharmaceutical compns. comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.
 IT 676471-19-5 676471-20-8 676471-22-0
 676471-23-1 676471-25-3 676471-26-4
 676471-27-5 676471-40-2 676471-41-3
 676471-42-4 676471-49-1 676471-50-4
 676471-51-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (modified GLP-1 peptides with increased biol. potency in the treatment of glucose metabolism disorders, insulin resistance, and related

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Conditions)
 RN 676471-19-5 CAPLUS
 CN L-Arginine, N-(2-ethoxybenzoyl)-L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PAGE 1-B



L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PAGE 1-D



PAGE 1-C



PAGE 1-E



Page 17

=> s gravel d?/au;s peri k?/au;s abribat t?/au;s habi a?/au
L10 108 GRAVEL D?/AU

L11 55 PERI K?/AU

L12 38 ABRIBAT T?/AU

L13 13 HABI A?/AU

=> s l1 and l11 and l12 andl13

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 11:23:19
SAMPLE SCREEN SEARCH COMPLETED - 4057 TO ITERATE

24.6% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 77321 TO 84959
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L1

L15 0 L14

MISSING OPERATOR L12 ANDL13

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l10 and l11 and l12 andl13

MISSING OPERATOR L12 ANDL13

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l10 and l11 and l12 and l13

L16 1 L10 AND L11 AND L12 AND L13

=> d ibib abs

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:287858 CAPLUS
DOCUMENT NUMBER: 140:298100
TITLE: Modified GLP-1 peptides with increased biol. potency
in the treatment of glucose metabolism disorders,
insulin resistance, and related conditions
INVENTOR(S): Gravel, Denis; Peri, Krishna;
Abribat, Thierry; Habi, Abdelkrim
PATENT ASSIGNEE(S): Theratechnologies Inc., Can.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029081	A2	20040408	WO 2003-CA1470	20030925
WO 2004029081	A3	20040722		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004127412	A1	20040701	US 2001-671340	20030925
PRIORITY APPLN. INFO.:			US 2002-413171P	P 20020925

OTHER SOURCE(S): MARPAT 140:298100
AB The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:
X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Y (SEQ ID NO.1), wherein
X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2 and Gly-OH. Moreover, the present invention relates to pharmaceutical compns. comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.

=> fil medl,biosis,embase;s l16

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.10	198.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-1.46

FILE 'MEDLINE' ENTERED AT 11:24:04 ON 22 JUN 2005

FILE 'BIOSIS' ENTERED AT 11:24:04 ON 22 JUN 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:24:04 ON 22 JUN 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

L17 0 FILE MEDLINE
L18 0 FILE BIOSIS
L19 0 FILE EMBASE

TOTAL FOR ALL FILES

L20 0 L16

=> s (glp1 or (glucagon like peptide(w)1))

L21 1645 FILE MEDLINE
L22 2143 FILE BIOSIS
L23 1982 FILE EMBASE

TOTAL FOR ALL FILES

L24 5770 (GLP1 OR (GLUCAGON LIKE PEPTIDE(W) 1))

=> s (l10 and l11 and l12 and l13) and l24

L25 0 FILE MEDLINE
L26 0 FILE BIOSIS
L27 0 FILE EMBASE

TOTAL FOR ALL FILES

L28 0 (L10 AND L11 AND L12 AND L13) AND L24

=> del his y

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.55	201.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.46

FILE 'REGISTRY' ENTERED AT 11:24:46 ON 22 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2005 HIGHEST RN 852656-52-1
DICTIONARY FILE UPDATES: 21 JUN 2005 HIGHEST RN 852656-52-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>